The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

Publié en janvier 2020 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Is CCL18 a potential biomarker of type-2 asthma?

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Publication précédente

How can we minimise the use of regular oral corticosteroids in asthma? (vol 29, 190085, 2020)

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Publication suivante